In yesterday’s Wall Street session, Rocket Pharmaceuticals Inc (NASDAQ:RCKT) shares traded at $2.48, up 6.44% from the previous session.
RCKT stock price is now -62.74% away from the 50-day moving average and -80.13% away from the 200-day moving average. The market capitalization of the company currently stands at $267.19M.
With the price target maintained at $7, Morgan Stanley recently Downgraded its rating from Overweight to Equal-Weight for Rocket Pharmaceuticals Inc (NASDAQ: RCKT). On May 28, 2025, Leerink Partners Downgraded its previous ‘Outperform’ rating to ‘Market Perform’ on the stock keeping its target price maintained at $8, while ‘JP Morgan’ rates the stock as ‘Neutral’
In other news, Militello John, insider sold 357 shares of the company’s stock on May 20 ’25. The stock was sold for $2,301 at an average price of $6.45. Upon completion of the transaction, the insider now directly owns 64,027 shares in the company, valued at $0.16 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 20 ’25, Schwartz Jonathan David sold 801 shares of the business’s stock. A total of $5,163 was realized by selling the stock at an average price of $6.45. This leaves the insider owning 235,255 shares of the company worth $0.58 million. A total of 7.39% of the company’s stock is owned by insiders.
During the past 12 months, Rocket Pharmaceuticals Inc has had a low of $2.19 and a high of $26.98. As of last week, the company has a debt-to-equity ratio of 0.06, a current ratio of 9.19, and a quick ratio of 9.19.
The company reported revenue of $64.39 million for the quarter, compared to $67.38 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -4.43 percent.
